---
title: "Biotech and Hygiene Stocks Outperform as Viva, Soft Report Double-Digit H1 Growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300663578.md"
description: "Viva Biotech's H1 revenue rose 21% on new CDMO projects, while Soft International posted 25% growth. Both outperformed Hang Seng Index in September, signaling sector-specific momentum amid broader market volatility."
datetime: "2026-10-01T09:14:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300663578.md)
  - [en](https://longbridge.com/en/news/300663578.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300663578.md)
generator: "portal-rs"
---

# Biotech and Hygiene Stocks Outperform as Viva, Soft Report Double-Digit H1 Growth

Viva Biotech (1873.HK) reported 21% year-on-year revenue growth for H1 2026, driven by two new commercialization projects at Langhua Pharmaceutical, which saw a 47% revenue surge. Despite bottom-line pressure, the stock rose 11.83% in the week of September 19, outperforming the Hang Seng Index by 140 basis points amid AI-driven CRO sector optimism.

Soft International (2569.HK) posted 25% revenue growth to CNY 549.31 million in the same period, with net profit up 9.2%. The Shishi nonwoven fabric facility expansion, set for completion in late 2026, will support 2027 production ramp-up. Rising sales expenses from digital marketing pushed margins to 34%, maintaining profitability amid sector headwinds.

The dual outperformance highlights niche strength in Hong Kong's small-cap segment, where targeted growth narratives are gaining traction. Both companies leveraged operational milestones rather than broad market trends to drive investor interest during September's volatile trading environment.

### Related Stocks

- [01873.HK](https://longbridge.com/en/quote/01873.HK.md)
- [02569.HK](https://longbridge.com/en/quote/02569.HK.md)

## Related News & Research

- [10:57 ETViva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth](https://longbridge.com/en/news/297064309.md)
- [Viva Biotech grants 6.22 million RSUs to CDMO staff at HK$ 1.08 each](https://longbridge.com/en/news/290927873.md)
- [Viva Biotech FY26 H1 net profit falls 32.1% to RMB 100.9 million; revenue rises 21% to RMB 1.01 billion](https://longbridge.com/en/news/297025777.md)
- [Soft International says FY2025 operations carry no international sanctions breach risk](https://longbridge.com/en/news/292061491.md)
- [Soft International FY26 H1 profit rises 9.2% to RMB 33.33 million; revenue climbs 25% to RMB 549.31 million](https://longbridge.com/en/news/297168549.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**